News & Updates
Filter by Specialty:
Ritlecitinib efficacy sustained up to 3 years in ALLEGRO trials
Ritlecitinib 50 mg demonstrates clinically meaningful efficacy up to 36 months in individuals with alopecia areata (AA) in the phase IIb/III ALLEGRO and ongoing phase III ALLEGRO-LT trials.
Ritlecitinib efficacy sustained up to 3 years in ALLEGRO trials
07 Oct 2025
Long-term bimekizumab delivers durable efficacy in plaque psoriasis
Treatment with bimekizumab for 4 years results in satisfactory levels of clinical and health-related quality of life responses, reports a study. The majority of patients with moderate-to-severe plaque psoriasis achieve near-complete skin clearance, while nearly two-thirds have complete skin clearance.
Long-term bimekizumab delivers durable efficacy in plaque psoriasis
25 Sep 2025
Higher serum vitamin D levels may lower risks of death, CVD in psoriasis patients
Individuals with psoriasis may benefit from an increased level of serum 25-hydroxivitamin D (25[OH]D), which has shown an association with a reduced risk of overall mortality and cardiovascular disease (CVD) in a recent study.
Higher serum vitamin D levels may lower risks of death, CVD in psoriasis patients
24 Sep 2025
Cell harvesting device delivers repigmentation in stable vitiligo lesions
A cell harvesting device that prepares autologous skin cell suspension (ASCS) offers a simple yet accessible technique for melanocyte transplantation in patients with vitiligo, a study has shown.
